Romlusevimab - Brii Biosciences
Alternative Names: BRII 198Latest Information Update: 13 Jul 2022
At a glance
- Originator The Third People's Hospital of Shenzhen; Tsinghua University
- Developer Brii Biosciences; TSB Therapeutics (Beijing) CO.LTD
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 13 Jul 2022 Phase-I clinical trials in COVID-2019 infections (In volunteers) in China (IV) (NCT04479644)
- 23 Apr 2021 Brii Biosciences and TSB Therapeutics completes a phase I trial for COVID-2019 infections (In volunteers) in China (IV) (NCT04479644)
- 01 Dec 2020 Brii Biosciences and TSB Therapeutics completes enrolment in its phase I trial for COVID-2019 infections (In volunteers) in China (IV) (NCT04479644)